2 no-brainer ASX 200 shares to buy next week

It's not hard to see why these quality companies could be great long term investment options.

| More on:
A man is shocked about the explosion happening out of his brain.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

There are a lot of quality companies for investors to choose from on the Australian share market.

But two excellent ASX 200 shares that stand out as no-brainers for me are listed below. Here's why analysts think they could be top buys:

ResMed Inc. (ASX: RMD)

ResMed could be a no-brainer ASX 200 share to buy now. It is one of the world's leading sleep disorder treatment companies.

This certainly is a great market to lead. For example, analysts estimate that obstructive sleep apnoea (OSA) could afflict over a billion people globally. And with the vast majority of these sufferers undiagnosed, there's a huge growth runway ahead for ResMed, its technology, and software solutions.

Bell Potter rates the company highly and has it on its favoured list with a buy rating and $36.00 price target. It commented:

The market for OSA and chronic obstructive pulmonary disease (COPD) remains under penetrated, and we expect industry volume growth to continue in the 6-8% range for the foreseeable future. In this regard, the competitive dynamics are very much in favour of RMD due to the Philips recall and improving semiconductor availability. Looking ahead, ResMed continues to expect device sales to be sequentially higher throughout CY2023. Furthermore, ResMed is well-positioned to build on its dominant share even after Philips returns to the global market, with the launch of its latest continuous positive airway pressure (CPAP) device, the Air Sense 11.

Xero Ltd (ASX: XRO)

Another no-brainer ASX 200 share for investors to consider buying is cloud accounting platform provider Xero.

It has been growing at a rapid rate in recent years thanks to the shift online and the quality and popularity of its platform. At the last count, the company had 4.16 million subscribers globally.

The good news is that Goldman Sachs believes its growth still has a very long way to go and estimates its market opportunity to be 100 million+ small businesses. In response to its full year results last week, the broker has reiterated its conviction buy rating with an improved price target of $164.00. The broker commented:

We see Xero as very well-placed to take advantage of the digitisation of SMBs globally, driven by compelling efficiency benefits and regulatory tailwinds, with >100mn SMBs worldwide representing a >NZ$100bn TAM. Given the company's pivot to profitable growth and corresponding faster earnings ramp, we see an attractive entry point into a global growth story with Xero our preferred large-cap technology name in ANZ – the stock is Buy rated.

Motley Fool contributor James Mickleboro has positions in ResMed and Xero. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Goldman Sachs Group, ResMed, and Xero. The Motley Fool Australia has positions in and has recommended ResMed and Xero. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Growth Shares

Five young people sit in a row having fun and interacting with their mobile phones.
Growth Shares

7 excellent ASX growth shares to buy next week

Analysts think growth investors should be buying these stocks.

Read more »

Man waiting for his flight and looking at his phone.
Growth Shares

Near its 52-week low, this ASX growth stock could be the bargain of the year!

I think this stock could be a leading opportunity.

Read more »

A happy young couple lie on a wooden deck using a skateboard for a pillow.
Growth Shares

2 top ASX growth shares to buy today and hold for 10 years

Analysts are very bullish on the outlooks of these buy-rated shares.

Read more »

Person handing out $100 notes, symbolising ex-dividend date.
Growth Shares

What are the best ASX shares to buy with $500 in 2024?

Analysts are bullish on these shares for good reason. Let's find out why.

Read more »

three businessmen high five each other outside an office building with graphic images of graphs and metrics superimposed on the shot.
Growth Shares

5 top ASX growth shares to buy in June

Analysts think growth investors should be snapping up these stocks while they can.

Read more »

A man holding a packaging box with a recycle symbol on it gives the thumbs up.
Industrials Shares

This ASX growth stock just leapt 6% on international expansion plans

The ASX growth stock is shrugging off the broader market malaise on Monday.

Read more »

A woman shows her phone screen and points up.
Growth Shares

1 ASX share on the cusp of profitability

This growth stock is rocketing towards positive financials.

Read more »

happy investor, share price rise, increase, up
Growth Shares

Analysts say these 5 ASX 200 growth shares are top buys

These stocks could be great options for growth investors this month.

Read more »